Category: 2016

QLIMS Qlik Sense Reporting Application Now Available!

OnQ Software is proud to announce it’s new QLIMS Qlik Sense application!

Developed in conjunction with leading data visualisation experts and certified Qlik partner’s, AtoBi, QLIMS can now extend on it’s comprehensive lab management features to more easily provide critical data to the user’s fingertips

The QLIMS application contains the following visualizations:

  • Lab Management Dashboard
  • KPI Tracking
  • Batch/Sample/Test Analysis
  • Customer Analysis
  • Cost Analysis
  • Site Analysis

Qlik® Sense offers a cutting edge visualization and discovery experience in a
smart, responsive, HTML5 client that allows people to quickly explore information
and gain critical insights. Qlik Sense is built to promote the use of human intuition
in all areas of the user experience.

For those who wish to further integrate other software packages into Qlik Sense to provide a complete picture of your organisation, AtoBi have a proven track record in helping to break down data barriers.

Enquire today for a demonstration.

 

Learn More

OnQ Software offering Clarity LIMS development services

After a long period as distributors of Basespace Clarity LIMS by Genologics, an Illumina company, OnQ Software is now officially certified under the CCAD developers program.

Two core features of Clarity LIMS have been how scalable and extensible it is as a platform and OnQ Software can now further assist customers to maximise the effectiveness of the IT ecosystem and achieve further lab automation.
The services which OnQ Software is offering Clarity LIMS customers in Australia, New Zealand and South East Asia are:
  • Instrument integration through the API and Lab Instrument Toolkit
  • Lab Logic assistance
  • Other integration services
Learn More

Northern Ireland leads in National Digital Pathology Research Programme

A national digital molecular pathology research programme led by the Belfast Cancer Research UK (CRUK) Center has been awarded the highly competitive CRUK Accelerator Award. Using PathXL software, this programme will link a number of major UK research centers, support multicenter collaboration in cancer research and use digital pathology to drive molecular pathology, immuno-oncology and the delivery of precision medicine.

August 19, 2015
Considered the ideal translational research environment, the CRUK Belfast center was selected to lead the programme and, over the next 5 years, through collaboration and training with consortium centers will seek to embed digital pathology within an extensive tissue and molecular oncology programme. It will also allow the consortium to drive digital pathology standards, consistency and interoperability across their centers, which include: University of Southampton, University of Manchester, University College London, Institute of Cancer Research and University of Newcastle.
PathXL Xplore™ software for digital pathology research management will be central to the delivery of this programme, providing the backbone for an integrated CRUK digital pathology network, managing multiple image formats, supporting the exchange of image and analytical data between centers, accelerating pathology workflow and establishing a UK-wide digital pathology infrastructure for standardization. PathXL TissueMark™ software will be used for automated tumor identification, molecular profiling and next generation sequencing in solid tumors, and as a means of improving sample quality and tumor sufficiency in molecular pathology.
PathXL software will also be used in conjunction with third party image analysis platforms to establish multicenter standards in digital pathology and new quantitative image analysis and computer vision technology in immuno-oncology.
Software and training will be rolled out during the first 12–18months of the programme across the five key UK university centers with significant expansion across the QUB existing central facilities.
Professor David Waugh, Director of the Centre for Cancer Centre and Cell Biology, said:
“The selection of this research programme submitted by the Belfast CRUK Centre is further proof that Queen’s cancer researchers are at the cutting edge of the latest innovations to improve outcomes for cancer patients across the world. Through this new research programme we will develop knowledge that can inform the targeted use of immunotherapeutic agents in cancer patients.”
“We are thrilled to receive this award and I congratulate my colleagues Prof Peter Hamilton and Prof Manuel Salto-Tellez, in leading this successful bid. It is further recognition of the powerful alliance that our Centre is forging with local and international industry to deliver new advances in cancer care”.
Des Speed, CEO of PathXL said:
“We are delighted that this innovative research project is progressing to implementation, and are looking forward to working with all centers in the consortium.
It is very exciting to be at the forefront of this UK-wide strategy for digital and molecular pathology in cancer, which has the potential to drive dramatic change. This award is further recognition that Northern Ireland is leading the way in developing digital pathology, and of the strength of the PathXL software platform.”

About PathXL

PathXL is a global pioneer in the use of web-based solutions for digital pathology, and provides innovative software for use in drug discovery research, clinical sectors, biomarker analysis and education. Their product for the automated identification and annotation of tumor tissue, TissueMark, was awarded the Frost and Sullivan 2014 European New Product Innovation Award for Automated Image Analysis for Digital Pathology.

About Belfast CRUK Center

CRUK researchers in Belfast are experts at identifying faulty genes and molecules in tumors. Many clinical trials in Belfast target these genes and molecules to test potential new ways to diagnose and treat cancer, especially hard-to-treat and more advanced cancers. Bringing together the best teams from Queen’s University Belfast, the Belfast Health and Social Care Trust and other local organizations to help beat cancer sooner.
Source – http://www.pathxl.com/news/northern-ireland-leads-in-national-digital-pathology-research-programme
For sales enquiries in Asia Pacific Region please contact OnQ Software – sales@onqsoft.com.au
Learn More

UK NEQAS for Molecular Genetics selects PathXL Software to support Molecular Pathology EQA Scheme

United Kingdom National External Quality Assessment Service (UK NEQAS) for Molecular Genetics choose PathXL digital pathology software to run a national scheme to assess consistency of tumour analysis for molecular pathology testing, as part of ensuring the high quality standard of Genomics England 100,000 Genome Project.
Belfast, Northern Ireland, November 30, 2015.
PathXL are proud to have been selected by UK NEQAS for Molecular Genetics as the digital pathology provider to support their innovative quality assurance scheme aiming to examine the accuracy in tumour identification and quantification on H&E samples by Genomic Medicine Centre (GMC) laboratories taking part in the 100,000 Genome Project.
PathXL are proud to have been selected by UK NEQAS for Molecular Genetics as the digital pathology provider to support their innovative quality assurance scheme aiming to examine the accuracy in tumour identification and quantification on H&E samples by Genomic Medicine Centre (GMC) laboratories taking part in the 100,000 Genome Project.
Molecular pathology and nucleic extraction in solid tumour relies on the pathological review of H&E stained tissue sections to annotate tumour regions for enrichment by macrodissection. This enables the estimation of the proportion of tumour nuclei within macrodissected areas which is necessary to ensure sample quality, sufficiency of tumour DNA for analysis and ultimately the precision of the molecular test result. For the 100,000 Genome Project this is critical to deliver high quality whole genome sequencing and allow accurate interpretation of the variants detected. It is known that the annotation of tumour and estimation of percentage of tumour nuclei can be highly variable between pathologists and between laboratories, which may lead to inaccurate molecular profiling and false negative results. Thus, there is a need to measure the degree of variation between laboratories and standardize approaches to tumour annotation and analysis to promote high quality testing.
As well as facilitating the viewing of the slides, PathXL EQA software allows for all questions to be recorded within it, including annotations for macrodissection. Individuals from participating molecular pathology laboratories will be asked to mark the regions of tumour they deem appropriate for macrodissection, drawing the boundary using PathXL’s EQA. They will then be prompted to make an estimation of the cellularity across the slide image and the percentage of tumour area within the annotated region.
Dr Sandi Deans, Scheme Director
“The molecular pathology tissue assessment module developed in collaboration with PathXL will help drive high standards and good quality molecular pathology testing across the country. This will initially be part of the 100,000 Genomes project and will then be developed to all laboratories providing a clinical molecular pathology testing service.”
Des Speed, PathXL CEO
“PathXL exists to provide cutting edge software in Digital Pathology. We are delighted to be supporting UK NEQAS in this very important project to enhance the work of Genomics England.”
About PathXL
PathXL is a global pioneer in the use of web-based solutions for digital pathology, and provides innovative software for use in drug discovery research, biomarker analysis and education. Their product for the automated identification and annotation of tumour tissue, TissueMark, was awarded the Frost and Sullivan 2014 European New Product Innovation Award for Automated Image Analysis for Digital Pathology.
About UK NEQAS for Molecular Genetics
UK NEQAS for Molecular Genetics provides external quality assessment for a range of inherited diseases and acquired disorders currently tested in diagnostic molecular laboratories. The Scheme gives objective information and advice to clinical laboratories throughout laboratory molecular medicine on the quality of their analytical and interpretative performance, in order to help them provide accurate and reliable test results and advice to clinicians, which facilitates optimal patient care. Advances in our understanding of genetic diseases has led to a revolution in testing technologies. UK NEQAS for Molecular Genetics is committed to providing external quality assessment in this rapidly evolving field which includes bespoke assessments to ensure the quality of the samples being accepted into the 100,000 Genomes project.
www.ukneqas-molgen.org.uk
Source – http://www.pathxl.com/news/uk-neqas-for-molecular-genetics-selects-pathxl-software-to-support-molecular-pathology-eqa-scheme
For sales enquiries in Asia Pacific Region please contact OnQ Software – sales@onqsoft.com.au
Learn More